🔗 Share this article

As the United States undertakes historic revisions to its immunization schedules, an unexpected name appears in a surprising turn: Tracy Beth Høeg, a Danish American sports medicine doctor and public health researcher who rose to prominence by casting doubt on Covid vaccines during the pandemic and has concentrated on potential deaths after Covid immunization in her short time at the FDA.

Planned Shifts to Pediatric Vaccine Program

Public health authorities were set to announce major revisions to the childhood vaccination calendar in December, synchronizing the US with the Danish national calendar, sources say – a major change that would place the US out of step with a large portion of the global community with insufficient data for public health gain. This reveal has been pushed back until the coming year.

Instead of the director of the vaccine center, Tracy Beth Høeg is scheduled to present at the meeting. She was newly appointed temporary leader of the FDA’s drug evaluation center, the fifth individual to head the division this calendar year.

A New Direction at the FDA

Høeg's temporary position could signify a strengthened alliance between the pharmaceutical and vaccine centers as Dr. Høeg and Prasad solidify control at the agency – and it signals a renewed priority upon reevaluating long-standing immunizations at the FDA.

The new acting director has repeatedly called for halting certain pediatric shot schedules in the US so as to align more in line with the Danish model, a society with comprehensive healthcare and a citizenry approximately the size of Wisconsin’s.

In her initial comments, she has persisted in emphasizing on vaccination policy – typically the responsibility of Prasad, director of the FDA’s CBER – as opposed to medication approval.

Doubts Over Expertise

Høeg has no obvious track record in pharmaceutical research, oversight or management, which has been customary for previous heads of the biologics center. She has been employed at the FDA as a top consultant to the FDA chief and CBER since earlier this year.

“She doesn’t seem to have any of the qualifications” for running the CDER, remarked Jonathan Howard. “She lacks experience running a clinical trial. She lacks experience in leading a sizeable institution. She has no expertise in drug approvals.”

Previous heads of CBER would “grasp laws and regulations and the research of drug development”, commented Dr. Janet Woodcock. “Frankly, she doesn’t have the kind of background that former directors who headed CBER have had.”

CDER has an immense portfolio at the FDA, Woodcock emphasized.

“Many people just focuses on the new drug program, but the off-patent medication office clears thousands of generic medications. There’s a biosimilars program, over-the-counter program and more, and all of those must be managed,” Dr. Woodcock said. “The area you neglect, that is precisely what that I always told people is going to come back to haunt you.”

There is also, a significant administrative aspect to the role, which oversees more than 5,000 staff members. “It is a huge management job, if you execute it properly,” she said.

Official Statement and Contentious Initiatives

When asked about concerns about Høeg’s credentials and whether this selection signifies increased cooperation among FDA leaders on vaccines, a representative said that the “concerns stem from incorrect presumptions”.

“This background matches the duties of her position,” the official stated, noting the period Høeg spent counseling the FDA commissioner on “pharmaceutical safety and regulatory science, including computational safety modeling and immunization monitoring”.

As acting director, Dr. Høeg assumes responsibility for the agency head's new fast-track approval initiative, a contentious one-day therapy clearance system that apparently troubled her predecessors. “By what process are these drugs being selected for this voucher program? Who is making the calls?” Dr. Howard asked. “There’s a lot of confidentiality going on at the regulatory body right now.”

Overall, he said, “the FDA seems to be moving towards less stringent rules of pharmaceuticals, except for vaccines.”

Established Track Record on Vaccines

With immunizations, Dr. Høeg has a more documented, if troubling, track record, critics said. She released a study using unverified crowd-sourced reports to assess the incidence of heart inflammation following Covid vaccination. She counseled the Florida chief medical officer Joseph Ladapo, who was said to have altered data to suggest COVID-19 vaccines are more dangerous than they are.

Among her “desired changes” for the new government encompassed revising rules for recently developed shots and halting “optional” immunizations, she stated post-election on a podcast. At the FDA, Høeg has according to sources floated the idea of preventing teenage boys from obtaining COVID-19 vaccinations.

“She is an all-around dogmatist who commences with her conclusions and tailors the evidence to fit the science in a extremely disingenuous, untruthful way,” Dr. Howard said.

Gaining Influence and a “Campaign of Retribution”

Høeg became part of fellow skeptics, {like|